Conference on Q1 FY2024
(April 1, 2024 to June 30, 2024)
Financial Results

Sumitomo Pharma Co., Ltd.

July 31, 2024

Sumitomo Pharma
Innovation today, healthier tomorrows

Disclaimer Regarding Forward-looking Statements

This material contains forecasts, projections, goals, plans, and other forward-looking statements regarding the Group's financial results and other data. Such forward-looking statements are based on the Company's assumptions, estimates, outlook, and other judgments made in light of information available at the time of disclosure of such statements and involve both known and unknown risks and uncertainties.

Accordingly, forecasts, plans, goals, and other statements may not be realized as described, and actual financial results, success/failure or progress of development, and other projections may differ materially from those presented herein.

Information concerning pharmaceuticals and medical devices (including those under development) contained herein is not intended as advertising or as medical advice.

Financial Results for Q1 FY2024

Business Operation Policies and Initiatives for Regrowth

- **Expanding revenue** In order to maximize the value of the three key products (ORGOVYX®, MYFEMBREE®, GEMTESA®) early, aim to achieve revenue of approx. 130 billion yen from the combined sales of the three key products in FY2024

  ⇒ Total revenue of the three key products shows strong progress towards meeting the plan as of Q1 FY2024

- **Reducing costs** The Group will make concerted efforts to accelerate streamlining by increasing efficiency in organizational operations and trimming costs to the minimum

  ✓ North America segment: Structural reforms (workforce reduction) have been completed in FY2023

  ✓ Japan segment: As part of the structural reform for Japan business reconstruction, the Company decided to implement an early retirement program

  ⇒ SG&A and R&D expenses in each segment are progressing as planned as of Q1 FY2024

- **Securing seeds for future business growth**

  ✓ Promote two development programs (TP-3654, DSP-5336) in the Oncology area and the regenerative medicine/cell therapy development program (CT1-DAP001/DSP-1083 for Parkinson's disease), which are expected to bring product creations to market during the period of the Mid-term Business Plan 2027

  ✓ Continue to invest in HLCR011 for retinal pigment epithelium tear, SMP-3124 for solid tumors, DSP-3077 for retinitis pigmentosa, and other programs that are a part of seeds for future business growth

  ⇒ Started NDA submission preparation for CT1-DAP001/DSP-1083 in Japan and signed a clinical collaboration agreement with GSK to evaluate the combination of nuvisertib (TP-3654) with momelotinib* in a Phase 1/2 study

(refer to page 14 for details on Major Progress in Clinical Development)

* Therapeutic agent for myelofibrosis with inhibitory effects on JAK1, JAK2, and activin receptor type 1

Financial Results for Q1 FY2024 (Core Basis)

The forecasts are not revised

Billions of JPY

	Q1YTD FY2023 Results	Q1YTD FY2024 Results	Change			FY2024	
			Value	FX impact	%	May 14 forecasts	Progress %
Revenue	75.7	**90.7**	15.0	7.2	19.8	338.0	26.8
Cost of sales	30.4	**34.9**	4.5	2.5	14.9	138.0	25.3
Gross profit	45.3	**55.7**	10.5	4.7	23.1	200.0	27.9
SG&A expenses	61.8	**43.8**	(18.0)	3.8	(29.2)	169.0	25.9
R&D expenses	22.8	**12.8**	(10.0)	0.6	(43.8)	50.0	25.6
Other operating income/expenses	5.9	**(0.0)**	(5.9)	—		20.0	
Core operating profit	(33.5)	**(0.9)**	32.6	0.0	—	1.0	—
Non-recurring items (negative number indicates net expense)	(18.1)	**(2.2)**	15.9			(1.0)	
Operating profit	(51.6)	**(3.1)**	48.5		—	0.0	—
Finance income/costs	20.5	**20.3**	(0.2)			(18.0)	
Profit before taxes	(31.1)	**17.2**	48.3		—	(18.0)	
Income tax expenses	7.8	**1.3**	(6.5)			(2.0)	
Net profit	(38.9)	**15.9**	54.8		—	(16.0)	—
Net profit attributable to owners of the parent	(38.9)	**15.9**	54.8		—	(16.0)	—

Average rates:
Q1 FY2023 Results : 1US$ = ¥137.50, 1RMB = ¥19.57
Q1 FY2024 Results : 1US$ = ¥155.86, 1RMB = ¥21.48
FY2024 forecasts : 1US$ = ¥145.00, 1RMB = ¥20.00

Period end rates:
As of the end of March 2024 : 1US$ = ¥151.33, 1RMB = ¥20.84
As of the end of June 2024 : 1US$ = ¥161.03, 1RMB = ¥22.05

- Revenue increased due to the growth of three key products, etc.
- SG&A expenses and R&D expenses decreased significantly due to the effects of business structure improvements and reductions through selection and concentration of R&D investments
- Other operating income/expenses:
  - Q1 FY2023: Share transfer of Sumitomo Pharma Animal Health Co., Ltd.
- Non-recurring items:
  - Q1 FY2024: Business structure improvement expenses in North America
  - Q1 FY2023: Business structure improvement expenses in North America

Financial Results for Q1 FY2024 (Core Basis) - vs. Q1 FY2024 Plans

Billions of JPY

	Q1YTD FY2024 Plans	**Q1YTD FY2024 Results**	Change			
			Value	%	FX impact	% (w/o FX)
Revenue	81.2	**90.7**	9.5	111.7	4.4	106.2
Cost of sales	31.5	**34.9**	3.4	110.8	1.7	105.4
Gross profit	49.7	**55.7**	6.1	112.2	2.7	106.7
SG&A expenses	47.2	**43.8**	(3.4)	92.7	2.3	87.9
R&D expenses	13.3	**12.8**	(0.5)	96.5	0.4	93.7
Other operating income/expenses	—	**(0.0)**	(0.0)		—	
Core operating profit	(10.9)	**(0.9)**	10.0	—	(0.1)	—

Average rates:
Q1 FY2024 Results : 1US$ = ¥155.86, 1RMB = ¥21.48
FY2024 Plans : 1US$ = ¥145.00, 1RMB = ¥20.00

Sumitomo Pharma

Revenue of Major Products in North America

North America	Q1YTD FY2023 Results (Millions of USD)	Q1YTD FY2024 Results (Millions of USD)	Change (Millions of USD)	Q1YTD FY2023 Results (Billions of JPY)	Q1YTD FY2024 Results (Billions of JPY)	Change Value (Billions of JPY)	Change FX impact (Billions of JPY)	Change %	FY2024 May 14 forecasts Millions of USD	FY2024 May 14 forecasts Billions of JPY	FY2024 JPY-basis Progess %
ORGOVYX®	68	**108**	40	9.3	**16.8**	7.4	2.0	79.7	400	57.9	29.0
MYFEMBREE®	13	**19**	6	1.8	**3.0**	1.2	0.4	67.7	124	17.9	16.8
GEMTESA®	63	**78**	15	8.7	**12.1**	3.4	1.4	39.3	380	55.0	22.1
APTIOM®	58	**65**	7	7.9	**10.2**	2.2	1.2	27.9	201	29.1	34.9
RETHYMIC®	11	**11**	(0)	1.5	**1.7**	0.2	0.2	13.4	49	7.2	23.6
Others	12	**20**	7	1.7	**3.1**	1.4	0.3	80.2	216	31.6	25.5
Export products/ One-time revenue, etc. *	33	**32**	(1)	4.5	**5.0**	0.5	0.6	11.1			
Total	258	**332**	75	35.5	**51.8**	16.4	6.1	46.1	1,370	198.7	26.1

(Ref.) Achievement rate against Q1 YTD plans for three key products

Million of USD

Plans	Results	%
86	108	125.5
22	19	88.4
79	78	98.2

- Revenue of three key products increased generally as planned
- Sales of APTIOM® increased due to true-up of rebates, etc.

* Major items included in One-time revenue, etc.

Q1 FY2023	Deferred revenue from the collaboration with Pfizer of $29M	Q1 FY2024	Deferred revenue from the collaboration with Pfizer of $29M

Average rates:
Q1 FY2023 Results : 1US$ = ¥137.50
Q1 FY2024 Results : 1US$ = ¥155.86

Sumitomo Pharma

Financial Results for Q1 FY2024

ORGOVYX®

Plan for Q1 YTD FY2024	Actual for Q1 YTD FY2024	YoY comparison	Influence of volume and price against actual (VS plan)	
$86M	**$108M (125% to plan)**	**Approx. 59% increase**	Volume	$15M
			Price	$7M

- Share in ADT Market*1

  Products Share June 2024: 7% (March 2024: 6%)

- Volume grew more than expected due to the changes in the medication benefit design for Medicare Part D

  Price was higher than expected due to the lower-than-anticipated returns and coverage gap

Quarterly Volume Trends*2

(number of bottles, estimation)



Topic for Sales and Marketing

- Recorded the highest number of new patients starts in May 2024
- Prescription growth has been confirmed in all account segments, with significant growth in Urology Clinics with in-office dispensing and Academic Centers/Integrated Delivery Networks (Oncology)
  - ✓ Continued communication to patients and HCPs about the changes in the medication benefit design for Medicare Part D from Jan. 2024
  - ✓ Focused on driving awareness and education on the updated NCCN guidelines that recognize ORGOVYX® as a recommended ADT option for advanced prostate cancer patients

*1 Internal calculation based on information licensed from IQVIA: NSP Volume for the period 3/1 to 3/31, 2024 and 6/1 to 6/30, 2024 reflecting estimates of real-world activity.
*2 Internal calculation

Financial Results for Q1 FY2024

MYFEMBREE®

Myfembree® (relugolix, estradiol, and norethindrone acetate) tablets 40 mg, 1 mg, 0.5 mg

Plan for Q1 YTD FY2024	Actual for Q1 YTD FY2024	YoY comparison	Influence of volume and price against actual (VS plan)	
$22M	**$19M (88% to plan)**	**Approx. 46% increase**	Volume	($3M)
			Price	$1M

- Rx Share in Oral GnRH antagonists Market*1 June 2024
  - ✓ TRx 47% (UF*2 : 87% EM*3: 22%)
    (Mar. 2024: 44%, 84%, 20%)
  - ✓ NBRx 50% (UF: 92% EM: 21%)
    (Mar. 2024: 47%, 91%, 20%)

- Volume grew less than expected due to the lower-than-expected market growth of GnRH antagonists and market share in EM
  Price was favorable due to the lower-than-expected Co-pay cards costs

Quarterly Volume Trends*4
(number of bottles, estimation)



Topic for Sales and Marketing

- Strategy remains focused on attaining share leadership; achieved NBRx share leadership (combined UF and EM) for first time in oral GnRH antagonist market in May 2024
- Launched consumer advertising campaign to coincide with endometriosis awareness month in Mar. 2024 which resulted in a sharp increase in consumer EM-related search and MYFEMBREE® website activity

*1 Source: *Symphony Health, an ICON plc Company, Metys®, June 1, 2024, to June 30, 2024 and March 1, 2024 to March 31, 2024.*, *2 uterine fibroids, *3 endometriosis,
*4 Source: *Symphony Health, an ICON plc Company, Metys®, April 1, 2021, to June 30, 2024.*

Financial Results for Q1 FY2024

GEMTESA®

Plan for Q1 YTD FY2024	Actual for Q1 YTD FY2024	YoY comparison	Influence of volume and price against actual (VS plan)	
$79M	**$78M (98% to plan)**	**Approx. 23% increase**	Volume	($3M)
			Price	$2M

- Rx Share in β3 Market*1 June 2024

  TRx 28%, NBRx 26% (March 2024: 25%, 35%)

- Volume was generally as planned, but slightly lower-than-expected in non-pharmacy channels

  Price was favorable due to the lower-than-anticipated returns and coverage gap

Quarterly Volume Trends*2

(number of bottles, estimation)



Topic for Sales and Marketing

- GEMTESA® volume has continued to grow, reaching all time highs in May 2024 despite the launch of generic mirabegron in Apr. 2024

  (No revision to FY2024 forecast as of Q1 FY2024)

- Promoted the fact that GEMTESA® has no warnings regarding hypertension because approx. 60% of patients with overactive bladder also have hypertension

*1 This is based on information licensed from IQVIA: NPA for the period 3/1 to 3/31, 2024 and 6/1 to 6/30, 2024 reflecting estimates of real-world activity. All rights reserved.

*2 Converted pill volume to number of bottles (30 tablets/bottle) based on information licensed from IQVIA: NPA for the period 4/1, 2021 to 6/30, 2024 reflecting estimates of real-world activity. All rights reserved.

Revenue of Major Products in Japan & Asia

Billions of JPY

	Q1YTD FY2023 Results	Q1YTD FY2024 Results	Change		FY2024	
			Value	%	May 14 forecasts	Progress %
Japan						
Equa®/EquMet®	8.2	**7.4**	(0.8)	(10.0)	26.3	28.0
LATUDA®	2.8	**3.4**	0.5	18.3	13.0	25.9
TWYMEEG®	1.2	**1.7**	0.6	49.6	11.3	15.3
METGLUCO®	1.9	**1.9**	0.0	0.5	7.4	25.9
LONASEN® Tape	0.9	**1.1**	0.2	26.3	4.4	25.5
TRERIEF®	4.4	**1.5**	(3.0)	(67.0)	2.1	69.8
AG products	2.3	**2.8**	0.5	20.2	11.1	25.3
Others	6.8	**5.1**	(1.6)	(23.9)	24.7	29.1
Export products/ One-time revenue, etc.	1.9	**2.1**	0.2	10.4		
Total	30.4	**27.0**	(3.4)	(11.2)	100.3	26.9
Asia						
MEROPEN® （China）	4.4	**6.4**	1.9	43.0	21.2	30.0
Others	5.4	**5.5**	0.1	2.3	17.8	31.1
Total	9.9	**11.9**	2.0	20.6	39.0	30.5

Note: Sales of each product in Japan are shown by invoice price

Japan

- Sales of LATUDA®, TWYMEEG®, and LONASEN® Tape continue to grow
- Sales of TRERIEF® decreased due to loss of exclusivity
- Total impact of NHI drug price revision (¥1.7B)

Asia

- MEROPEN® (China) revenue increased despite the impact of Volume-Based Procurement application

Sumitomo Pharma

Segment Information (Core Basis)

Billions of JPY

		Japan	North America	Asia	Total
Q1YTD FY2024	Revenue	27.0	51.8	11.9	90.7
	Cost of sales	13.2	18.5	3.2	34.9
	Gross profit	13.8	33.3	8.7	55.7
	SG&A expenses	9.7	31.1	3.0	43.8
	Core segment profit	4.0	2.1	5.7	11.9
	R&D expenses				12.8
	Core operating profit				(0.9)
Q1YTD FY2023	Revenue	30.4	35.5	9.9	75.7
	Cost of sales	14.7	13.0	2.7	30.4
	Gross profit	15.6	22.5	7.1	45.3
	SG&A expenses	12.8	46.2	2.8	61.8
	Core segment profit	2.8	(23.7)	4.3	(16.6)
	R&D expenses				22.8
	Core operating profit				(33.5)
Change	Revenue	(3.4)	16.4	2.0	15.0
	SG&A expenses	(3.1)	(15.1)	0.2	(18.0)
	Core segment profit	1.2	25.9	1.4	28.5
	R&D expenses				(10.0)
	Core operating profit				32.6

Japan

- Despite a decrease in gross profit due to decline in revenue, core segment profit increase due to decrease in selling, general and administrative expenses

North America

- In addition to increase in gross profit resulted from revenue growth, core segment profit increased significantly due to decrease in selling, general and administrative expenses

Asia

- Core segment profit increased owing to increased gross profit due to increased revenue

Research and Development

Research and Development

Development Pipeline (as of July 31, 2024)

: Psychiatry & Neurology : Oncology : Others

Revisions since the announcement in May 2024 are shown in red

Area	Phase 1		Phase 2	Phase 3	NDA submitted
Japan	**DSP-0187** (Narcolepsy) **DSP-0378** (Dravet syndrome, Lennox–Gastaut syndrome)	**nuvisertib (TP-3654)** (Myelofibrosis) **enzomenib (DSP-5336)** (Acute leukemia) **DSP-0390** (Glioblastoma) **SMP-3124** (Solid tumors) **KSP-1007** (Complicated urinary tract and intra-abdominal infections, Hospital-acquired bacterial pneumonia)	**Allo iPS cell-derived products** (Parkinson's disease/ Investigator-initiated study) **Allo iPS cell-derived products** (Retinal pigment epithelium tear)		
U.S.	**DSP-0038** (Alzheimer's disease psychosis) **DSP-3456** (Treatment resistant depression) **DSP-2342** (To be determined)	**nuvisertib (TP-3654)** (Myelofibrosis) **enzomenib (DSP-5336)** (Acute leukemia) **DSP-0390** (Glioblastoma) **SMP-3124** (Solid tumors) **KSP-1007** (Complicated urinary tract and intra-abdominal infections, Hospital-acquired bacterial pneumonia)	**Allo iPS cell-derived products** (Parkinson's disease/ Investigator-initiated study/ Company-sponsored clinical study)		**GEMTESA® (vibegron)** (New indication: OAB in men with BPH)
China				**vibegron** (Overactive bladder)	
Europe	**fH1/DSP-0546LP** (Influenza)				

Major Progress in Clinical Development

- **Allo iPS cell-derived products (dopaminergic neural progenitor cells)**
  Japan: Parkinson's disease (Phase 1/2)
  - Obtained study results in the investigator-initiated study by Kyoto University, and preparing for NDA submission
- **nuvisertib (TP-3654)**
  - Signed a clinical collaboration agreement with GSK to evaluate the combination of nuvisertib (TP-3654) with momelotinib* in a Phase 1/2 study
- **enzomenib (DSP-5336)**
  - At the European Hematology Association (EHA) 2024 Congress in June 2024, presented the new clinical data from the ongoing Phase 1/2 study as an oral presentation (more details on the next page)
  - Received Fast Track Designation for the treatment of relapsed or refractory acute myeloid leukemia with mixed lineage leukemia rearrangement (MLLr) or nucleophosmin 1 mutation (NPM1m) in June 2024
- **SMP-3124**
  Japan: Started Phase 1/2 study for solid tumors

* Therapeutic agent for myelofibrosis with inhibitory effects on JAK1, JAK2, and activin receptor type 1

From data presented at EHA 2024

Oncology Area: Phase 1/2 Study of enzomenib (DSP-5336) (Acute Leukemia, Interim Results)

Patients with MLL rearrangements (MLLr) or NPM1 mutations (NPM1m) experience consistent blast reduction across all dose level



CR: complete response
CRh: complete remission with partial hematologic recovery
CRi: complete remission with incomplete hematologic recovery
MLFS: morphologic leukemia-free state

Safety (57 patients)

- ✓ Well-tolerated with no dose limiting toxicity (DLT)
- ✓ No significant cardiac signal nor treatment-related discontinuations or deaths
- ✓ No differentiation syndrome (DS) prophylaxis was needed, and 5.7% (3/57 patients) of DS reported was manageable and did not result in death or discontinuation of enzomenib

Efficacy (21 patients (received 140 mg twice-daily or higher, with enzomenib target mutations (MLLr or NPM1m*)) (excludes patients with prior menin inhibitor treatment)

- ✓ Objective response was observed with 57% (12/21 patients)
- ✓ Complete remission or complete remission with partial hematologic recovery (CR/CRh) observed in 24% (5/21 patients)

Future Plan

- ✓ The pivotal part of the monotherapy study is scheduled to start in FY2024

* Approximately 30% of acute myeloid leukemia (AML) patients have NPM1m and 5-10% of AML patients have MLLr

Sumitomo Pharma

Appendix

＜Contents＞

Appendix (Financial Results for Q1 FY2024)

Financial Results for Q1 FY2024 (Full Basis)

Billions of JPY

	Q1YTD FY2023 Results	Q1YTD FY2024 Results	Change	
			Value	%
Revenue	75.7	90.7	15.0	19.8
Cost of sales	30.4	34.9	4.5	14.9
Gross profit	45.3	55.7	10.5	23.1
SG&A expenses	74.9	45.4	(29.5)	(39.4)
R&D expenses	27.8	13.1	(14.7)	(52.9)
Other operating income and expenses	5.9	(0.3)	(6.3)	
Operating profit	(51.6)	(3.1)	48.5	—
Finance income and costs	20.5	20.3	(0.2)	
Profit before taxes	(31.1)	17.2	48.3	—
Income tax expenses	7.8	1.3	(6.5)	
Net profit	(38.9)	15.9	54.8	—
Net profit attributable to owners of the parent	(38.9)	15.9	54.8	—

Appendix (Financial Results for Q1 FY2024)

Financial Position and Cash Flow

Billions of JPY

B / S	As of March 2024	As of June 2024	Change
Assets	907.5	868.9	(38.6)
Goodwill / Intangible assets	395.4	418.4	22.9
Other financial assets (Non-current)	161.7	41.3	(120.4)
Cash and deposit / Short-term loan receivable	29.0	78.4	49.4
Liabilities	751.4	708.0	(43.4)
Bonds and borrowings	418.9	390.1	(28.8)
Deferred tax liabilities	38.2	15.7	(22.5)
Income taxes payable	1.3	20.5	19.2
Equity	156.1	160.9	4.8
Attributable to owners of the parent	156.1	160.9	4.8
(Ratio of equity attributable to owners of the parent to total assets)	17.2%	18.5%	

C / F	Q1 FY2023	Q1 FY2024	Change
Operating CF	(130.2)	(25.1)	105.1
Investment CF	38.5	102.1	63.7
Financial CF	33.6	(29.2)	(62.8)
Cash and cash equivalents	94.5	78.4	(16.1)
(Operating funds)	94.5	78.4	(16.1)

Increase due to FX rate impact

Decrease due to sales of investment securities

Decrease in short-term borrowings

Decrease due to sales of investment securities

Increase due to sales of investment securities

Q1 FY2023: In addition to net loss, decrease in provisions and increase in corporate income tax payments
Q1 FY2024: Although net profit improved, expenditures for business structure improvements had a large impact

Q1 FY2023: Proceeds from sales of Sumitomo Pharma Animal Health Co., Ltd. shares and investment securities
Q1 FY2024: Proceeds from sales of investment securities

Q1 FY2023: Increase in short-term borrowings
Q1 FY2024: Decrease in short-term borrowings

Sumitomo Pharma

Appendix (Research and Development)

Main Events / Targets for FY2024 (as of July 31, 2024)

Revisions since the announcement in May 2024 are shown in red

Psychiatry & Neurology	☐ Allogeneic iPS cell-derived products (Parkinson's disease): Submit NDA in Japan ☐ Allogeneic iPS cell-derived products (Parkinson's disease): Obtain approval in Japan ☐ Allogeneic iPS cell-derived products (Parkinson's disease): First patient implantation in the U.S. ☐ Allogeneic iPS cell-derived products (Retinal pigment epithelium tear): Start a randomized part of Phase 1/2 study in Japan ☐ Advance early Phase studies
Oncology	☐ nuvisertib (TP-3654) (☐ Advance Phase 1/2 study ☑ Start the combination part of the study with a JAK inhibitor) ☐ enzomenib (DSP-5336) (☐ Advance Phase 1/2 study ☐ Start the pivotal part of the monotherapy study) ☐ SMP-3124 (☐ Advance Phase 1/2 study in the U.S. ☑ Start the same Phase 1/2 study in Japan)
Others	☐ vibegron: Obtain approval for overactive bladder (OAB) with benign prostatic hyperplasia in the U.S. ☐ Advance early Phase studies of universal influenza vaccine and others
Frontier	☐ Promoting the current themes and generating evidence data for maximizing the value of the launched products

Appendix (Research and Development)

Product Launch Target (as of July 31, 2024)

Psychiatry & Neurology | Oncology | Others

No revisions since the announcement in May 2024



* Under review for launch target

Sumitomo Pharma

Appendix (Research and Development)

Regenerative Medicine/Cell Therapy Launched Product and Development Pipeline (as of July 31, 2024)

No revisions since the announcement in May 2024

Brand name/Cell type Product code	Indications	JP/ US	Pre-clinical	Clinical research	Phase 1/2	Phase 3	Approval application	Approval→ Launch
RETHYMIC®	Congenital athymia	US						●
Dopaminergic neural progenitor cells (Allo iPS cell-derived) CT1-DAP001/DSP-1083	Parkinson's disease	JP US			●1 ●4 ●5			Launch Target* (FY2024)
Retinal pigment epithelial cells (Allo iPS cell-derived) HLCR011	Retinal pigment epithelium tear	JP			●5			
Photoreceptor (3D) (Allo iPS cell-derived) DSP-3077	Retinitis pigmentosa	JP US	●	●2				
Neural progenitor cells (Allo iPS cell-derived)	Spinal cord injury	JP US		●3				
Nephron progenitor cells (organ) (Auto/ Allo iPS cell-based induced)	Kidney failure	JP/ US	●					

1. Kyoto University Hospital 2. Kobe City Eye Hospital 3. Keio University Hospital 4. University of California San Diego School of Medicine
5. Company-sponsored clinical study * Subject to conditional and time-limited approval

Appendix (Research and Development)

Frontier Business Product Launch Target (as of July 31, 2024)

Revisions since the announcement in May 2024 are shown in red

: Non-medical device
: Medical device

	FY2024	FY2025	FY2026	FY2027	FY2028
VR contents (BehaVR, Inc.)			**Social Anxiety Disorder** (US)	**VR contents in other disease area**	
MELTz®		**"MELTz® Portable" (finger exercise training system)** (JP)			
Wearable EEG meter (NeuroSky Co., Ltd.)		**Depression** (JP)		**Depression** (JP)	
Violet Light (Tsubota Laboratory Incorporated)		**Depression / Dementia** (JP)		**Depression / Dementia** (JP)	

Deleted MELTIN from MELTz® in the table because FrontAct Co., Ltd., the Company's consolidated subsidiary, has acquired the medical business from MELTIN


Sumitomo Pharma
Innovation today, healthier tomorrows